Before Ozempic, Wegovy, Mounjaro and Zepbound, there was Lotte Bjerre Knudsen.
In the 1990s, the young scientist at the Danish drug company Novo Nordisk was trying to unlock the key to a new technology for treating Type 2 diabetes. To her bosses, Lotte’s project, which focused on a hormone called GLP-1, looked like a distraction.
But as Lotte fought to save her diabetes project from the chopping block, she couldn’t have imagined how much of an impact her breakthrough would have. Her work would pave the way for a hit drug called Ozempic. And it would unleash a new class of blockbuster drugs, pitting two companies in a race to become the world’s first trillion-dollar pharmaceutical company by market cap.
Listen to Part 1 of “Trillion Dollar Shot” now.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Elon Musk’s Unusual Relationships With Women at SpaceX
New York’s U-Turn on a Plan to Reduce Traffic
Shein: Fast Fashion, Slow IPO
Trillion Dollar Shot, Episode 4: The Disruptors
‘It Came out of Nowhere’: The Rise of Dr Pepper
Why Biden Is Cracking Down on Asylum at the Border
Behind Closed Doors, Biden’s Age is Showing
A Conversation with Alphabet’s Captain of Moonshots
Mexico Has a New President. Will She Be Different?
Trillion Dollar Shot, Episode 3: Brad
The Origin Story of Trump's Guilty Verdict
The Big Short: China Edition
The Trustbuster Taking on Ticketmaster
$2.8 Billion for College Athletes and a New World for the NCAA
Introducing Science Vs - Ozempic: Is It Scarier Than We Thought?
The First Person to Get Elon Musk’s Neuralink Brain Chip
Could Paris Hilton Create the 'Next Disney?'
Years After Surfside Collapse, Florida Condos Are In Crisis
Why Israel and Hamas Could Be Headed Into a Forever War
Did ‘Roaring Kitty’ Just Spark a Meme Stock Sequel?
Create your
podcast in
minutes
It is Free
WSJ What’s News
WSJ Your Money Briefing
WSJ Opinion: Potomac Watch
The Daily
Today, Explained